Современные представления о лабораторных маркерах метаболического синдрома

С. А. Айрапетян; А. Н. Шишкин

doi:10.32415/jscientia_2025_11_2_5-20

Авторы

С. А. Айрапетян Санкт-Петербургский государственный университет https://orcid.org/0000-0001-9239-4294
А. Н. Шишкин Санкт-Петербургский государственный университет

https://doi.org/10.32415/jscientia_2025_11_2_5-20

Ключевые слова:

метаболический синдром, лабораторная диагностика, маркеры, ожирение, сахарный диабет

Аннотация

Метаболический синдром широко распространён среди людей во всём мире. Неблагоприятное воздействие практически на все органы и ткани организма наряду с высокой встречаемостью делает метаболический синдром актуальной проблемой современности. Начиная со второй половины 1990‑х годов, международные сообщества в области здравоохранения предлагали свои критерии диагностики метаболического синдрома. Однако все предложенные критерии обладали высокой вариабельностью и не позволяли проводить раннюю диагностику синдрома. Оценка новых лабораторных маркеров метаболического синдрома может оказаться более эффективным методом ранней диагностики. В данном обзоре мы постарались систематизировать известные к настоящему времени маркеры и показать значимость каждого из них для диагностики метаболического синдрома.

Биографии авторов

С. А. Айрапетян, Санкт-Петербургский государственный университет

аспирант кафедры факультетской терапии

А. Н. Шишкин, Санкт-Петербургский государственный университет

доктор медицинских наук, профессор, заведующий кафедрой факультетской терапии

Библиографические ссылки

Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12. https://doi.org/10.1007/s11906-018-0812-z. EDN: VFJEKJ

Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev. 2008;29(7):777-822. https://doi.org/10.1210/er.2008-0024

Ротарь ОP, Либис РА, Исаева ЕН, и др. Распространённость метаболического синдрома в разных городах РФ. Российский кардиологический журнал. 2012;(2):55-62. [Rotar OR, Libis RA, Isaeva EN, et al. Prevalence of metabolic syndrome in different cities of the Russian Federation. Russ Card J. 2012;(2):55-62. (in Russ.)]. EDN: OWOEPZ

Després JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition. 1993;9(5):452-459.

Albrink MJ, Krauss RM, Lindgrem FT, et al. Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population. Lipids. 1980;15(9):668-676. https://doi.org/10.1007/BF02534017

Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149(7):1514-1520. https://doi.org/10.1001/archinte.149.7.1514

DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173-194. https://doi.org/10.2337/diacare.14.3.173. EDN: XYMZUX

Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-553. https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497. https://doi.org/10.1001/jama.285.19.2486

Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404

Bloomgarden ZT. Symposium: Debating the Metabolic Syndrome. Medscape Conference Coverage, based on selected sessions. Am Diabetes Assoc 66th Scientific Sessions. 2006;6:9-13

National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. 1998;98.

Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644

Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Практическая медицина. 2010;44:81-101. [Recommendations of experts of the All-Russian Scientific Society of Cardiologists on the diagnosis and treatment of metabolic syndrome. Practical Medicine. 2010;44:81-101. (in Russ.)].

Experts’ consensus on the interdisciplinary approach towards the management, diagnostics, and treatment of patients with metabolic syndrome. Cardiovasc Ther Prev. 2013;12(6):41-82. EDN: RSYQYP

Zahedi AS, Zarkesh M, Sedaghati-Khayat B, et al. Insulin resistance-related circulating predictive markers in the metabolic syndrome: a systematic review in the Iranian population. J Diabetes Metab Disord. 2023;23(1):199-213. https://doi.org/10.1007/s40200-023-01347-6. EDN: TVQAXN

Neeland IJ, Lim S, Tchernof A, et al. Metabolic syndrome. Nat Rev Dis Primers. 2024;10(1):77. https://doi.org/10.1038/s41572-024-00563-5. EDN: DJYGNX

Ahima RS. Overview of metabolic syndrome. In: Metabolic Syndrome: A Comprehensive Textbook. Cham: Springer International Publishing; 2024:3-14. https://doi.org/10.1007/978-3-031-40116-9_1

Frankenberg ADV, Reis AF, Gerchman F. Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review. Arch Endocrinol Metab. 2017;61(6):614-622. https://doi.org/10.1590/2359-3997000000316

Abdalla MA, Abubaker J, Abu-Farha M, et al. Investigating the Role of FABP4 in Diabetes and Obesity and the Influence of Age and Ethnicity: A Comprehensive Analysis of a Cohort from the KEDP-Study. Int J Mol Sci. 2024;25(9):4578. https://doi.org/10.3390/ijms25094578. EDN: RRLGAE

Sur G, Floca E, Kudor-Szabadi L, et al. The relevance of inflammatory markers in metabolic syndrome. Maedica (Bucur). 2014;9(1):15-18.

Kir S, Ekiz K, Alacam H, et ak. The Association Between Pro and Anti-Inflammatory Markers with the Components of Metabolic Syndrome. Acta Endocrinol (Buchar). 2019;15(4):430-435. https://doi.org/10.4183/aeb.2019.430

Шишкин АН. Метаболический синдром и риск развития сердечно-сосудистых осложнений. Университетский терапевтический вестник. 2023;5(S):258. [Shishkin AN. Metabolic syndrome and the risk of cardiovascular complications. Univ Ther J. 2023;5(S):258. (in Russ.)].

Swarup S, Ahmed I, Grigorova Y, et al. Metabolic syndrome. StatPearls [Internet]. 2024.

Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol. 2009;20(3):182-189. https://doi.org/10.1097/MOL.0b013e32832ac03e

Ridker PM, Pare G, Parker A, et al. Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study. Am J Hum Genet. 2008;82(5):1185-1192. https://doi.org/10.1016/j.ajhg.2008.03.015

Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51(5):1596-1600. https://doi.org/10.2337/diabetes.51.5.1596. EDN: EFNYVP

Abril-Ulloa V, Flores-Mateo G, Solà-Alberich R, et al. Ferritin levels and risk of metabolic syndrome: meta-analysis of observational studies. BMC Public Health. 2014;14:483. https://doi.org/10.1186/1471-2458-14-483. EDN: STMEVD

Orban E, Schwab S, Thorand B, Huth C. Association of iron indices and type 2 diabetes: a meta-analysis of observational studies. Diabetes Metab Res Rev. 2014;30(5):372-394. https://doi.org/10.1002/dmrr.2506

Suárez-Ortegón MF, Ensaldo-Carrasco E, Shi T, et al. Ferritin, metabolic syndrome and its components: A systematic review and meta-analysis. Atherosclerosis. 2018;275:97-106. https://doi.org/10.1016/j.atherosclerosis.2018.05.043

Fernández-Real JM, McClain D, Manco M. Mechanisms Linking Glucose Homeostasis and Iron Metabolism Toward the Onset and Progression of Type 2 Diabetes. Diabetes Care. 2015;38(11):2169-2176. https://doi.org/10.2337/dc14-3082

Kuwabara M, Fukuuchi T, Aoki Y, et al. Exploring the Multifaceted Nexus of Uric Acid and Health: A Review of Recent Studies on Diverse Diseases. Biomolecules. 2023;13(10):1519. https://doi.org/10.3390/biom13101519. EDN: PYNVPO

Maloberti A, Mengozzi A, Russo E, et al. The Results of the URRAH (Uric Acid Right for Heart Health) Project: A Focus on Hyperuricemia in Relation to Cardiovascular and Kidney Disease and its Role in Metabolic Dysregulation. High Blood Press Cardiovasc Prev. 2023;30(5):411-425. https://doi.org/10.1007/s40292-023-00602-4. EDN: KTPKPT

King C, Lanaspa MA, Jensen T, et al. Uric Acid as a Cause of the Metabolic Syndrome. Contrib Nephrol. 2018;192:88-102. https://doi.org/10.1159/000484283

Raya-Cano E, Vaquero-Abellán M, Molina-Luque R, et al. Association between metabolic syndrome and uric acid: a systematic review and meta-analysis. Sci Rep. 2022;12(1):18412. https://doi.org/10.1038/s41598-022-22025-2. EDN: RCHREJ

Guarner V, Rubio-Ruiz ME. Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease. Interdiscip Top Gerontol. 2015;40:99-106. https://doi.org/10.1159/000364934

Silveira Rossi JL, Barbalho SM, Reverete de Araujo R, et al. Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. Diabetes Metab Res Rev. 2022;38(3):e3502. https://doi.org/10.1002/dmrr.3502. EDN: AAKMWZ

Gao C, Gao S, Zhao R, et al. Association between systemic immune-inflammation index and cardiovascular-kidney-metabolic syndrome. Sci Rep. 2024;14(1):19151. https://doi.org/10.1038/s41598-024-69819-0. EDN: DSOZIA

Elgazar-Carmon V, Rudich A, Hadad N, Levy R. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J Lipid Res. 2008;49(9):1894-1903. https://doi.org/10.1194/jlr.M800132-JLR200

Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212-6222. https://doi.org/10.1158/1078-0432.CCR-14-0442

Zhao Y, Shao W, Zhu Q, et al. Association between systemic immune-inflammation index and metabolic syndrome and its components: results from the National Health and Nutrition Examination Survey 2011-2016. J Transl Med. 2023;21(1):691. https://doi.org/10.1186/s12967-023-04491-y. EDN: WHABUM

Mohammadi M, Gozashti MH, Aghadavood M, et al. Clinical Significance of Serum IL-6 and TNF-α Levels in Patients with Metabolic Syndrome. Rep Biochem Mol Biol. 2017;6(1):74-79. EDN: SXVQJH

Dattola A, Silvestri M, Bennardo L, et al. Role of Vitamins in Skin Health: a Systematic Review. Curr Nutr Rep. 2020;9(3):226-235. https://doi.org/10.1007/s13668-020-00322-4. EDN: QOFDOA

Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281. https://doi.org/10.1056/NEJMra070553. EDN: MMCTNV

Мальцев CВ. Современные аспекты применения витамина D в клинической практике. РМЖ. Мать и дитя. 2022;5(3):244-252. [Maltsev SV. Current perspectives of using vitamin D in clinical practice. Russian Journal of Woman and Child Health. 2022;5(3):244–252. (in Russ.)]. DOI 10.32364/2618-8430-2022-5-3-244-252. EDN: HWFHAZ

Ismailova A, White JH. Vitamin D, infections and immunity. Rev Endocr Metab Disord. 2022;23(2):265-277. https://doi.org/10.1007/s11154-021-09679-5.

Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000;164(5):2405-2411. https://doi.org/10.4049/jimmunol.164.5.2405

Argano C, Mirarchi L, Amodeo S, et al. The Role of Vitamin D and Its Molecular Bases in Insulin Resistance, Diabetes, Metabolic Syndrome, and Cardiovascular Disease: State of the Art. Int J Mol Sci. 2023;24(20):15485. https://doi.org/10.3390/ijms242015485. EDN: XAIZTK

Adamczak M, Wiecek A. The adipose tissue as an endocrine organ. Semin Nephrol. 2013;33(1):2-13. https://doi.org/10.1016/j.semnephrol.2012.12.008

Kumari R, Kumar S, Kant R. An update on metabolic syndrome: Metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetes Metab Syndr. 2019;13(4):2409-2417. https://doi.org/10.1016/j.dsx.2019.06.005

Kim JE, Kim JS, Jo MJ, et al. The Roles and Associated Mechanisms of Adipokines in Development of Metabolic Syndrome. Molecules. 2022;27(2):334. https://doi.org/10.3390/molecules27020334. EDN: QKNVHS

Филинюк ПЮ, Шишкин АН, Пчелин ИЮ, и др. Некоторые особенности коррекции дисфункции жировой ткани. Juvenis Scientia. 2023;9(6):6-17. [Filinyuk PY, Shishkin AN, Pchelin IY, et al. Some features of correction of adipose tissue dysfunction. Juvenis Scientia. 2023;9(6):6-17. (in Russ.)]. https://doi.org/10.32415/jscientia_2023_9_6_6-17. EDN: HFBEVZ

Izquierdo AG, Crujeiras AB, Casanueva FF, Carreira MC. Leptin, Obesity, and Leptin Resistance: Where Are We 25 Years Later?. Nutrients. 2019;11(11):2704. https://doi.org/10.3390/nu11112704. EDN: ADYWMQ

Hassanzadeh T, Maleki M, Saidijam M, Paoli M. Association between leptin gene G-2548A polymorphism with metabolic syndrome. J Res Med Sci. 2013;18(8):668-673

Jung D, Bucher F, Ryu S, et al. An adiponectin receptor agonist antibody stimulates glucose uptake and fatty-acid oxidation by activating AMP-activated protein kinase. Cytokine. 2020;126:154863. https://doi.org/10.1016/j.cyto.2019.154863. EDN: IZOMDD

Yokota T, Meka CS, Medina KL, et al. Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins. J Clin Invest. 2002;109(10):1303-1310. https://doi.org/10.1172/JCI14506

Ruan H, Dong LQ. Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol. 2016;8(2):101-109. https://doi.org/10.1093/jmcb/mjw014

Frankenberg ADV, Reis AF, Gerchman F. Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review. Arch Endocrinol Metab. 2017;61(6):614-622. https://doi.org/10.1590/2359-3997000000316

Falahi E, Khalkhali Rad AH, Roosta S. What is the best biomarker for metabolic syndrome diagnosis?. Diabetes Metab Syndr. 2015;9(4):366-372. https://doi.org/10.1016/j.dsx.2013.06.014

Agostinis-Sobrinho C, Vicente SECF, Norkiene S, et al. Is the Leptin/Adiponectin Ratio a Better Diagnostic Biomarker for Insulin Resistance than Leptin or Adiponectin Alone in Adolescents?. Children (Basel). 2022;9(8):1193. https://doi.org/10.3390/children9081193. EDN: NZSIIT

Laight DW, Kengatharan KM, Gopaul NK, et al. Investigation of oxidant stress and vasodepression to glyceryl trinitrate in the obese Zucker rat in vivo. Br J Pharmacol. 1998;125(4):895-901. https://doi.org/10.1038/sj.bjp.0702132

Hognogi LD, Simiti LV. The cardiovascular impact of visfatin - an inflammation predictor biomarker in metabolic syndrome. Clujul Med. 2016;89(3):322-326. https://doi.org/10.15386/cjmed-591

Jiang Y, Zhou L. The Value of Visfatin in the Prediction of Metabolic Syndrome: A Systematic Review and Meta-Analysis. Horm Metab Res. 2023;55(9):610-616. https://doi.org/10.1055/a-2051-6776. EDN: IBKYWM

Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307-312. https://doi.org/10.1038/35053000

Вербовой АФ, Шишкин АН, Вербовая НИ, и др. Резистин-маркер сердечно-сосудистых заболеваний. Ожирение и метаболизм. 2017;14(4):5-9. [Verbovoy AF, Shishkin AN, Verbovaya NI, et al. Resistin-marker of cardiovascular diseases. Obesity and Metabolism. 2017;14(4):5-9. (in Russ.)]. https://doi.org/10.14341/omet201745-9. EDN: YLAUKC

Su KZ, Li YR, Zhang D, et al. Relation of Circulating Resistin to Insulin Resistance in Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis. Front Physiol. 2019;10:1399. https://doi.org/10.3389/fphys.2019.01399. EDN: DCCUFJ

Fontana A, Spadaro S, Copetti M, et al. Association between resistin levels and all-cause and cardiovascular mortality: a new study and a systematic review and meta-analysis. PLoS One. 2015;10(3):e0120419. https://doi.org/10.1371/journal.pone.0120419

Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015;29(1):17-24. https://doi.org/10.1016/j.blre.2014.09.003. EDN: UTJWZT

Ploplis VA. Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease. Curr Drug Targets. 2011;12(12):1782-1789. https://doi.org/10.2174/138945011797635803

Uhl B, A Mittmann L, Dominik J, et al. uPA-PAI-1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils. EMBO Mol Med. 2021;13(6):e13110. https://doi.org/10.15252/emmm.202013110. EDN: NSXSNM

Wu J, Jing X, Du Q, et al. Disruption of the Clock Component Bmal1 in Mice Promotes Cancer Metastasis through the PAI-1-TGF-β-myoCAF-Dependent Mechanism. Adv Sci (Weinh). 2023;10(24):e2301505. https://doi.org/10.1002/advs.202301505. EDN: YIIOZJ

Vecchiola A, García K, González-Gómez LM, et al. Plasminogen Activator Inhibitor-1 and Adiponectin Are Associated With Metabolic Syndrome Components. Am J Hypertens. 2022;35(4):311-318. https://doi.org/10.1093/ajh/hpab138. EDN: VMIUTO

Chung JY, Hong J, Kim HJ, et al. White adipocyte-targeted dual gene silencing of FABP4/5 for anti-obesity, anti-inflammation and reversal of insulin resistance: Efficacy and comparison of administration routes. Biomaterials. 2021;279:121209. https://doi.org/10.1016/j.biomaterials.2021.121209. EDN: KDYBAM

Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs--mechanisms and therapeutic implications. Nat Rev Endocrinol. 2015;11(10):592-605. https://doi.org/10.1038/nrendo.2015.122

Furuhashi M. Fatty Acid-Binding Protein 4 in Cardiovascular and Metabolic Diseases. J Atheroscler Thromb. 2019;26(3):216-232. https://doi.org/10.5551/jat.48710. EDN: PTZPNG

Burak MF, Inouye KE, White A, et al. Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. Sci Transl Med. 2015;7(319):319ra205. https://doi.org/10.1126/scitranslmed.aac6336

Gorbenko O, Filonenko V, Gout I. Generation and characterization of monoclonal antibodies against FABP4. Hybridoma (Larchmt). 2006;25(2):86-90. https://doi.org/10.1089/hyb.2006.25.86. EDN: XLKFJB

Dashty M. A quick look at biochemistry: carbohydrate metabolism. Clin Biochem. 2013;46(15):1339-1352. https://doi.org/10.1016/j.clinbiochem.2013.04.027

Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999;83(9B):25F-29F. https://doi.org/10.1016/s0002-9149(99)00211-8

Li X, Li Z, Zhao M, et al. Skeletal Muscle Lipid Droplets and the Athlete’s Paradox. Cells. 2019;8(3):249. https://doi.org/10.3390/cells8030249. EDN: RJQBFR

Jung JY, Ryoo JH, Chung PW, et al. Association of fasting glucose and glycated hemoglobin with the long-term risk of incident metabolic syndrome: Korean Genome and Epidemiology Study (KoGES). Acta Diabetol. 2019;56(5):551-559. https://doi.org/10.1007/s00592-019-01290-0. EDN: BGJDRC

Lippi G, Targher G. Glycated hemoglobin (HbA1c): old dogmas, a new perspective?. Clin Chem Lab Med. 2010;48(5):609-614. https://doi.org/10.1515/cclm.2010.144. EDN: NZBQGX

Vasilev P, Shishkin A, Erofeev N, et al. Correlations between laser Doppler flowmetry spectral indicators and glycated hemoglobin level in patients with diabetic nephropathy. Nephrol Dial Transplant. 2024;39(1):1751-1189. https://doi.org/10.1093/ndt/gfae069.1751. EDN: MRKDHQ

Park SH, Yoon JS, Won KC, Lee HW. Usefulness of glycated hemoglobin as diagnostic criteria for metabolic syndrome. J Korean Med Sci. 2012;27(9):1057-1061. https://doi.org/10.3346/jkms.2012.27.9.1057

Ong KL, Tso AW, Lam KS, et al. Using glycosylated hemoglobin to define the metabolic syndrome in United States adults. Diabetes Care. 2010;33(8):1856-1858. https://doi.org/10.2337/dc10-0190

Templeman NM, Skovsø S, Page MM, et al. A causal role for hyperinsulinemia in obesity. J Endocrinol. 2017;232(3):R173-R183. https://doi.org/10.1530/JOE-16-0449

Ferrannini E, Gastaldelli A, Miyazaki Y, et al. beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005;90(1):493-500. https://doi.org/10.1210/jc.2004-1133

Nolan CJ, Prentki M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. Diab Vasc Dis Res. 2019;16(2):118-127. https://doi.org/10.1177/1479164119827611

Antuna-Puente B, Disse E, Rabasa-Lhoret R, et al. How can we measure insulin sensitivity/resistance?. Diabetes Metab. 2011;37(3):179-188. https://doi.org/10.1016/j.diabet.2011.01.002. EDN: OAORGX

González-González JG, Violante-Cumpa JR, Zambrano-Lucio M, et al. HOMA-IR as a predictor of Health Outcomes in Patients with Metabolic Risk Factors: A Systematic Review and Meta-analysis. High Blood Press Cardiovasc Prev. 2022;29(6):547-564. https://doi.org/10.1007/s40292-022-00542-5. EDN: ERSXFG

Румянцев АШ, Шишкин АН, Минкин СР, Шевелева МА. Особенности кардиоренального континуума у пациентов с метаболическим синдромом. Нефрология. 2016;20(5):75-83. [Rumyantsev AS, Shishkin AN, Minkin SR, Sheveleva MA. Features of the cardiorenal continuum in patients with metabolic syndrome. Nephrology. 2016;20(5):75-83.(In Russ.)]. EDN: WMWYIL

Liu X, Tao L, Cao K, et al. Association of high-density lipoprotein with development of metabolic syndrome components: a five-year follow-up in adults. BMC Public Health. 2015;15:412. https://doi.org/10.1186/s12889-015-1747-9. EDN: BYZWRC

Leiter LA, Lundman P, da Silva PM, et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med. 2011;28(11):1343-1351. https://doi.org/10.1111/j.1464-5491.2011.03360.x

Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368(9539):919-928. https://doi.org/10.1016/S0140-6736(06)69292-1

Kosmas CE, Rodriguez Polanco S, Bousvarou MD, et al. The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease. Diagnostics (Basel). 2023;13(5):929. https://doi.org/10.3390/diagnostics13050929. EDN: SPCDZF

Ramdas Nayak VK, Satheesh P, Shenoy MT, Kalra S. Triglyceride Glucose (TyG) Index: A surrogate biomarker of insulin resistance. J Pak Med Assoc. 2022;72(5):986-988. https://doi.org/10.47391/JPMA.22-63. EDN: YNMHXW

Son DH, Lee HS, Lee YJ, et al. Comparison of triglyceride-glucose index and HOMA-IR for predicting prevalence and incidence of metabolic syndrome. Nutr Metab Cardiovasc Dis. 2022;32(3):596-604. https://doi.org/10.1016/j.numecd.2021.11.017. EDN: MIFARQ

Chen J, Wu K, Lin Y, Huang M, Xie S. Association of triglyceride glucose index with all-cause and cardiovascular mortality in the general population. Cardiovasc Diabetol. 2023;22(1):320. https://doi.org/10.1186/s12933-023-02054-5. EDN: DMXVEM

Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021;119:154770. https://doi.org/10.1016/j.metabol.2021.154770. EDN: QKWCTG

Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500-514. https://doi.org/10.1016/j.tem.2021.04.008. EDN: ZCRJAA

Khalili P, Ayoobi F, Kahkesh Pour F, et al. Serum liver enzymes and metabolic syndrome from the Rafsanjan Cohort Study. J Investig Med. 2023;71(2):140-148. https://doi.org/10.1177/10815589221141830. EDN: YFBPRT

Raya-Cano E, Molina-Luque R, Vaquero-Abellán M, et al. Metabolic syndrome and transaminases: systematic review and meta-analysis. Diabetol Metab Syndr. 2023;15(1):220. https://doi.org/10.1186/s13098-023-01200-z. EDN: LSNGNO